Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Mayo Clinic
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- Pattern of F-18 Florbetapir uptake (Heterogeneous vs. Homogeneous, focal vs. diffuse)
研究概览
简要总结
The primary aim of this study will be to examine the diagnostic utility of 18-F Florbetapir PET/MR (Positron Emission Tomography/Magnetic Resonance) in imaging patients with pathologically-confirmed systemic amyloidosis involving the peripheral nerves and compare these results to non-amyloid diseased controls.
详细描述
Patients with pathologically proven amyloidosis involving the peripheral nervous system will undergo 18-F Florbetapir PET/MR on a GE (General Electric Healthcare) SIGNA PET/MR scanner. A control arm comprised of patients with pathologically-confirmed non-amyloid causes of peripheral neuropathy will also undergo 18-F Florbetapir PET/MR scanning. all images will be reviewed for peripheral nerve uptake.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults: 18-100
- •Pathologically-confirmed peripheral nerve amyloidosis or pathologically-confirmed non-amyloid causes of peripheral neuropathy
排除标准
- •Metallic devices that are not MR safe (cardiac pacers, stents, aneurysm coils, etc.)
- •Claustrophobia
- •BMI over 38
研究组 & 干预措施
Peripheral nerve amyloidosis
Patients with pathologically-confirmed peripheral nerve amyloidosis will undergo 18-F Florbetapir PET/MR scan on a GE SIGNA PET/MR scanner.
干预措施: 18-F Florbetapir PET/MR scan (Other)
结局指标
主要结局
Pattern of F-18 Florbetapir uptake (Heterogeneous vs. Homogeneous, focal vs. diffuse)
时间窗: 50-120 minutes post injection
Heterogeneous vs. Homogeneous, focal vs. diffuse. This is a categorical variable. There is not a quantitative or semi-quantitative scale that is appropriate.
Locations of peripheral nerve 18-F Florbetapir uptake
时间窗: 50-120 minutes post injection
Standardized uptake value (SUV)
次要结局
- Additional sites of 18-F Florbetapir uptake(50-120 minutes post injection)
- Pattern of contrast enhancement (Solid, heterogeneous or peripheral enhancement)(50-120 minutes post injection)
- Morphologic changes(50-120 minutes post injection)
- T1 and T2 characteristics (Hypointense, isointense or hyperintense relative to skeletal muscle)(50-120 minutes post injection)